HomeORGANIZATION
ORGANIZATION

FPMAJ Report Warns of Repercussions from Sovaldi Price Slash
(Jun.14.2016)

The re-pricing of Gilead Sciences’ hepatitis C drug Sovaldi (sofosbuvir) less than a year after launch will have negative fallout for the Japanese pharma market overall, the Federation of Pharmaceutical Manufacturers’ Associations of Japan (FPMAJ) warned in its report released ...
(LOG IN FOR FULL STORY)

News Calendar